Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs)

被引:71
作者
Barreca, ML
Carotti, A
Carrieri, A
Chimirri, A
Monforte, AM
Calace, MP
Rao, A
机构
[1] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy
[2] Univ Bari, Dipartimento Farmacochim, I-70125 Bari, Italy
[3] Univ Catanzaro, Fac Farm, I-88021 Catanzaro, Italy
关键词
D O I
10.1016/S0968-0896(99)00181-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A set of TIBO derivatives endowed with reverse transcriptase (RT) inhibitory activity were analyzed by comparative molecular field analysis (CoMFA). Besides conventional steric and electrostatic fields, molecular lipophilicity potential (MLP) was also used as a third field in CoMFA. An informative and statistically significant model (q(2) = 0.70, r(2) = 0.90, s = 0.46) was obtained by taking into account the three field types together. The key molecular determinants governing the RT inhibition by TIBO congeners were detected at the 3-D level by a careful analysis of the CoMFA isocontour maps. To challenge the predictive ability of the CoMFA model, an external set of thiazolobenzimidazole (TBZ) derivatives were examined. Good predictions, suggesting a similar binding mode for TIBO and TBZ derivatives, emerged. Flexible docking experiments on TBZ, TIBO and other NNIs confirmed common binding characteristics, as found out also by CoMFA, and moreover a good correlation between calculated binding energies and inhibitory potency was found. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2283 / 2292
页数:10
相关论文
共 39 条
[1]
3-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS OF 5-HT RECEPTOR-BINDING DATA FOR TETRAHYDROPYRIDINYLINDOLE DERIVATIVES - A COMPARISON OF THE HANSCH AND COMFA METHODS [J].
AGARWAL, A ;
PEARSON, PP ;
TAYLOR, EW ;
LI, HB ;
DAHLGREN, T ;
HERSLOF, M ;
YANG, YH ;
LAMBERT, G ;
NELSON, DL ;
REGAN, JW ;
MARTIN, AR .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (25) :4006-4014
[2]
[Anonymous], J COMP CHEM
[3]
[Anonymous], CH PI INTERACTION EV
[4]
BRESLIN HJ, 1995, J MED CHEM, V38, P771, DOI 10.1021/jm00005a005
[5]
BROTO P, 1984, EUR J MED CHEM, V19, P61
[6]
2-D and 3-D modeling of imidazoline receptor ligands: Insights into pharmacophore [J].
Carrieri, A ;
Brasili, L ;
Leonetti, F ;
Pigini, M ;
Giannella, M ;
Bousquet, P ;
Carotti, A .
BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (05) :843-856
[7]
CARRIERI A, 1994, FARMACO, V49, P573
[8]
CHIMIRRI A, 1991, FARMACO, V46, P925
[9]
CHIMIRRI A, 1991, FARMACO, V46, P817
[10]
Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles [J].
Chimirri, A ;
Grasso, S ;
Monforte, AM ;
Monforte, P ;
Rao, A ;
Zappala, M ;
Bruno, G ;
Nicolo, F ;
Pannecouque, C ;
Witvrouw, M ;
De Clercq, E .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1998, 9 (05) :431-438